LamdaGen Corporation

LamdaGen Corporation is an innovative technology company focused on developing and integrating powerful plasmonic biosensors for a wide range of applications. The company's flagship product, the LAuRA Digital Diagnostic System, utilizes proprietary plasmonic biosensors and patented Plasmonic Amplification Technology™ (PAT™) to enable rapid, high-sensitivity detection. This unique technology combines the speed and convenience of lateral flow assay (LFA) with the exceptional sensitivity and quantitation capabilities of microtiter plate enzyme-linked immunosorbent assays (ELISA). Founded in 2004 and based in the United States, LamdaGen operates at the forefront of the Biotechnology, Health Care, and Information Technology industries. The company's most recent investment was a $1.00M grant received on 27 June 2019 from the National Institute of Allergy and Infectious Diseases. As a technology holding company, LamdaGen follows a serial spin-off licensing model to optimize the value of its biosensor-based technologies. It leverages its expertise and intellectual property to expand into various sectors, including Food and Water Safety, Human Health, Animal Health, and Environmental Health. Through strategic partnerships with industry leaders, LamdaGen aims to apply its biosensor technology to a broad range of applications, facilitating significant advancements in diagnostic capabilities and enhancing overall safety and well-being. LamdaGen's vision is to revolutionize the field of biosensing by consistently pushing the boundaries of sensitivity, speed, and precision for commercial use. The company remains committed to delivering cutting-edge solutions that address critical needs across diverse industries, ultimately improving health outcomes and enabling more effective decision-making processes. Potential partners are invited to explore collaboration opportunities with LamdaGen.